ecancermedicalscience

Short Communication

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis, such as the COVID-19 pandemic

27 Apr 2020
Covadonga Marti, José I Sánchez-Méndez

The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care.

Related Articles

Mehak Trikha, Vanita Noronha, Minit Shah, Vijay Patil, Nandini Menon, Ajaykumar Singh, Pratik Chandrani, Omshree Shetty, Rajiv Kumar Kaushal, Trupti Pai, Amit Janu, Nilendu Purandare, Kumar Prabhash
Lisa Ximena Rodríguez Rojas, Liliana Doza Martínez, Jorge Andrés Olave Rodríguez, Sandra Eliana Murillo Rusynke, Paola Andrea Pérez Castellano, David Alexander Bolaños Beltrán, Helen Johana Ortiz Rojas, José Antonio Nastasi Catanese
Abhijit Shah, Surag KR, Anupam Choudhary, Kasi Viswanath, Krishnakanth AVB, Chaitanya Krishna, Padmaraj Hegde, Gayathri S, Swathi PM